Malta - inglise - Medicines Authority

midas pharma gmbh rheinstrasse 49, 55218 ingelheim, germany - ketoprofen - granules for oral solution - ketoprofen 25 mg - antiinflammatory and antirheumatic products

Malta - inglise - Medicines Authority

midas pharma gmbh rheinstrasse 49, 55218 ingelheim, germany - ketoprofen - granules for oral solution - ketoprofen 50 mg - antiinflammatory and antirheumatic products

Malta - inglise - Medicines Authority

g.l. pharma gmbh schlossplatz 1, 8502 lannach, austria - vildagliptin, metformin hydrochloride - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

Malta - inglise - Medicines Authority

g.l. pharma gmbh schlossplatz 1, 8502 lannach, austria - vildagliptin, metformin hydrochloride - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Malta - inglise - Medicines Authority

denk pharma gmbh & co. kg prinzregentenstrasse 79 81675 münchen , germany - apixaban - film-coated tablet - apixaban 2.5 mg - antithrombotic agents

Malta - inglise - Medicines Authority

denk pharma gmbh & co. kg prinzregentenstrasse 79 81675 münchen , germany - apixaban - film-coated tablet - apixaban 5 mg - antithrombotic agents

Euroopa Liit - inglise - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:* patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.

Euroopa Liit - inglise - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;patients suffering from acute coronary syndrome:- non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.

Euroopa Liit - inglise - EMA (European Medicines Agency)

astellas pharma gmbh - tacrolimus - dermatitis, atopic - other dermatological preparations - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

Malta - inglise - Medicines Authority

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - tadalafil - film-coated tablet - tadalafil 20 mg - urologicals